HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.

被引：0
|
作者：
Hearn, Jason W. D.
AbuAli, Ghada
Magi-Galluzzi, Cristina
Reddy, Chandana A.
Chang, Kai-Hsiung
Klein, Eric A.
Sharifi, Nima
机构：
[1] Cleveland Clin, Dept Radiat Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Cleveland Clin, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44106 USA
[3] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA
[4] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA
[5] Cleveland Clin, Dept Hematol & Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
[6] Cleveland Clin, Dept Canc Biol, Taussig Canc Inst, Cleveland, OH 44106 USA
[7] Cleveland Clin, Dept Urol, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.156
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
156
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
    Hearn, Jason W. D.
    AbuAli, Ghada
    Magi-Galluzzi, Cristina
    Reddy, Chandana A.
    Chang, Kai-Hsiung
    Klein, Eric A.
    Sharifi, Nima
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
    Hearn, Jason W. D.
    AbuAli, Ghada
    Reichard, Chad A.
    Reddy, Chandana A.
    Magi-Galluzzi, Cristina
    Chang, Kai-Hsiung
    Carlson, Rachel
    Rangel, Laureano J.
    Reagan, Kevin
    Davis, Brian
    Karnes, Jeffrey
    Kohli, Manish
    Tindall, Donald J.
    Klein, Eric A.
    Sharifi, Nima
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer
    Daniel Hettel
    Nima Sharifi
    Nature Reviews Urology, 2018, 15 : 191 - 196
  • [4] HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study
    Hearn, Jason W. D.
    AbuAli, Ghada
    Reichard, Chad A.
    Reddy, Chandana A.
    Magi-Galluzzi, Cristina
    Chang, Kai-Hsiung
    Carlson, Rachel
    Rangel, Laureano
    Reagan, Kevin
    Davis, Brian J.
    Karnes, R. Jeff Rey
    Kohli, Manish
    Tindall, Donald
    Klein, Eric A.
    Sharifi, Nima
    LANCET ONCOLOGY, 2016, 17 (10): : 1435 - 1444
  • [5] HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer
    Hettel, Daniel
    Sharifi, Nima
    NATURE REVIEWS UROLOGY, 2018, 15 (03) : 191 - 196
  • [6] HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer
    Fei-fei Han
    Lu-lu Ren
    Ling-ling Xuan
    Ya-li LV
    He Liu
    Li-li Gong
    Zhuo-ling An
    Li-hong Liu
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 103 - 112
  • [7] HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer
    Han, Fei-Fei
    Ren, Lu-Lu
    Xuan, Ling-Ling
    Lv, Ya-Li
    Liu, He
    Gong, Li-Li
    An, Zhuo-Ling
    Liu, Li-Hong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (01) : 103 - 112
  • [8] Re: HSD3B1 and Resistance to Androgen-Deprivation Therapy in Prostate Cancer: A Retrospective, Multicohort Study
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2017, 197 (01): : 150 - 150
  • [9] HSD3B1 genotype and response to androgen deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer.
    Hearn, Jason W. D.
    Xie, Wanling
    Nakabayashi, Mari
    Almassi, Nima
    Reichard, Chad A.
    Pomerantz, Mark
    Kantoff, Philip W.
    Sharifi, Nima
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Missense polymorphism in HSD3B1 in Japanese men treated with primary androgen-deprivation therapy for metastatic prostate cancer.
    Shiota, Masaki
    Fujimoto, Naohiro
    Imada, Kenjiro
    Kashiwagi, Eiji
    Takeuchi, Ario
    Inokuchi, Junichi
    Tatsugami, Katsunori
    Kajioka, Shunichi
    Eto, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345